Entheon Biomedical (ENBI) AI Stock Analysis

• Market Cap: $1.39M
• Dividend Yield: N/A
• Average Volume (3M): 9.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.35
• Revenue Growth: -100.00%
• EPS Growth: 11.63%
• Country: CA
• Employees: 1
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 13,858,926
• 10 Day Avg. Volume: 2,250
• 30 Day Avg. Volume: 9,612
• PEG Ratio: -0.49
• Price to Book (P/B): 2.41
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 36 Underperform
• Price Target: ―

Entheon Biomedical is facing significant financial and operational challenges, with ongoing losses, liquidity issues, and a weak technical position. The recent termination of an acquisition agreement adds to strategic uncertainties. The company’s negative valuation metrics reflect market skepticism about its future profitability. Overall, the stock presents high risk, with potential upside if strategic improvements are successfully implemented.

Entheon Biomedical Business Overview & Revenue Model

Company Description

Entheon Biomedical (ENBI) is a biotechnology company focused on the research and development of psychedelic-based therapeutic solutions to treat addiction and other mental health disorders. Operating within the biopharmaceutical sector, Entheon is dedicated to advancing the scientific understanding and clinical application of psychedelic compounds, particularly DMT (N,N-Dimethyltryptamine), to address unmet medical needs.

How the Company Makes Money

Entheon Biomedical generates revenue through a combination of research and development partnerships, licensing agreements, and potentially from future commercialization of therapeutic products. The company invests in clinical trials and scientific research to develop proprietary treatment protocols and compounds. Revenue streams may include collaborations with academic institutions, pharmaceutical companies, and healthcare providers, as well as potential government grants or funding for research in the mental health sector. Additionally, Entheon might seek monetization through intellectual property licensing once their psychedelic therapies are clinically validated and receive regulatory approval.

Entheon Biomedical Financial Statement Overview

Summary

Entheon Biomedical faces substantial financial hurdles with ongoing losses and liquidity issues. The lack of revenue in the latest period is concerning, though past periods showed some revenue growth. The absence of debt provides a stable financial base, but negative cash flow and profitability metrics underscore the need for strategic improvements. The company must focus on enhancing revenue generation and operational efficiency to improve its financial health.

Income Statement

The income statement shows significant challenges, as Entheon Biomedical has experienced declining total revenue, with no revenue recorded in the latest TTM period. Net income remains consistently negative, indicating ongoing losses. The EBIT and EBITDA margins are negative, reflecting unprofitable operations. However, there was a positive revenue growth in 2023 compared to 2022, which suggests some recovery potential in sales.

Balance Sheet

Entheon Biomedical's balance sheet indicates no debt, which is a strong point, reducing financial risk. The company maintains a positive equity ratio, suggesting a stable capital structure. However, the return on equity is negative due to continuous net losses, and the total assets have decreased over time, indicating potential asset management concerns.

Cash Flow

Cash flow analysis reveals significant cash outflows from operations and negative free cash flow, highlighting liquidity challenges. The company has relied on financing activities to support operations, as seen by the positive financing cash flows. However, the negative free cash flow to net income ratio suggests difficulties in converting earnings into cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	250.32K	189.68K	21.67K	0.00
Gross Profit	0.00	250.32K	187.58K	9.13K	-2.72K
EBITDA	-318.00K	13.99K	-3.60M	-8.21M	-1.64M
Net Income	-318.00K	-300.00K	-8.52M	-8.89M	-4.38M
Balance Sheet
Total Assets	185.14K	401.08K	769.22K	9.98M	4.47M
Cash, Cash Equivalents and Short-Term Investments	136.49K	344.63K	680.17K	2.05M	2.84M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	39.81K	85.33K	154.65K	927.71K	728.19K
Stockholders Equity	145.33K	315.75K	614.57K	9.05M	3.74M
Cash Flow
Free Cash Flow	-355.64K	-359.93K	-1.95M	-5.71M	-2.85M
Operating Cash Flow	-355.64K	-359.93K	-1.95M	-5.62M	-2.84M
Investing Cash Flow	0.00	24.40K	585.64K	-98.87K	1.08M
Financing Cash Flow	147.50K	0.00	0.00	4.98M	4.43M

Entheon Biomedical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ENBI, the sentiment is Negative. The current price of 0.1 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.10, and below the 200-day MA of 0.16, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.42 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ENBI.

Entheon Biomedical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NEO	71 Outperform	C$679.23M	―	-3.70%	2.42%	-12.01%	-698.83%
TRIP	51 Neutral	$16.04M	―	-30.44%	―	13.57%	-14.29%
Sector *	46 Neutral	C$197.02M	-3.33	-23.14%	2.65%	20.75%	-0.36%
CYBN	37 Underperform	C$1.97M	―	-42.90%	―	―	51.37%
ENBI	36 Underperform	$1.39M	―	-106.50%	―	-100.00%	11.63%

Entheon Biomedical Corporate Events

Entheon Biomedical Announces Board Changes

Entheon Biomedical Corp. has appointed Harrison Newlands to its Board of Directors, effective April 3, 2025. Newlands brings a wealth of experience in start-ups and capital markets, having co-founded and advised several companies in industries such as cannabis and electric vehicles. His appointment is expected to strengthen Entheon’s strategic positioning in the biotechnology sector. Meanwhile, Andrew Hegle has resigned from the board, and the company expressed gratitude for his contributions.

Spark’s Take on TSE:ENBI Stock

According to Spark, TipRanks’ AI Analyst, TSE:ENBI is a Underperform.

Entheon Biomedical’s overall stock score reflects significant financial challenges, including negative profitability and cash flow issues, compounded by a bearish technical outlook. The stock’s valuation is unattractive due to a negative P/E ratio and lack of dividend yield. The recent termination of an acquisition agreement further adds uncertainty to the company’s strategic direction.

To see Spark’s full report on TSE:ENBI stock, click here.

Entheon Biomedical Grants Incentive Stock Options to Directors

Entheon Biomedical Corp. has announced the issuance of incentive stock options to certain directors, allowing them to purchase up to 40,000 common shares at $0.145 per share over the next two years. This move is part of the company’s broader incentive stock option plan, aimed at aligning the interests of its directors with the company’s strategic goals, potentially impacting its operational dynamics and market positioning.

Entheon Biomedical Ends Acquisition Agreement with Mentis AI

Entheon Biomedical Corp. announced the termination of its agreement with Mentis AI, which involved acquiring all common shares of the latter. This development may impact Entheon’s strategic plans in the biotechnology sector, particularly in its focus on addiction treatment, and could have implications for stakeholders involved in the proposed acquisition.